EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

GluK2 Is a Target for Gene Therapy in Drug‐Resistant Temporal Lobe Epilepsy

Céline Boileau, Severine Deforges, Angélique Peret, Didier Scavarda, Fabrice Bartolomei iD, April Giles, Nicolas Partouche, Justine Gautron, Julio Viotti, Haley Janowitz iD, Guillaume Penchet, Cécile Marchal und 22 weitere

Annals of Neurology · 2023-10 · 94 (4) · 745-761

DOI: 10.1002/ana.26723 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 06.07.2023. Verfasst von Céline Boileau und 33 weiteren Autor:innen. Beteiligte Einrichtung: Aix-Marseille Univ. INSERM, Marseille, France. Hauptthemen laut MEDLINE: Epilepsy, Temporal Lobe, Drug Resistant Epilepsy, MicroRNAs. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agence Nationale de la Recherche, Centre National de la Recherche Scientifique, Inserm Transfert.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Temporal lobe epilepsy (TLE) is characterized by recurrent seizures generated in the limbic system, particularly in the hippocampus. In TLE, recurrent mossy fiber sprouting from dentate gyrus granule cells (DGCs) crea an aberrant epileptogenic network between DGCs which operates via ectopically expressed GluK2/GluK5‐containing kainate receptors (KARs). TLE patients are often resistant to anti‐seizure medications and suffer significant comorbidities; hence, there is an urgent need for novel therapies. Previously, we have shown that GluK2 knockout mice are protected from seizures. This study aims at providing evidence that downregulating KARs in the hippocampus using gene therapy reduces chronic epileptic discharges in TLE.

Methods

We combined molecular biology and electrophysiology in rodent models of TLE and in hippocampal slices surgically resected from patients with drug‐resistant TLE.

Results

Here, we confirmed the translational potential of KAR suppression using a non‐selective KAR antagonist that markedly attenuated interictal‐like epileptiform discharges (IEDs) in TLE patient‐derived hippocampal slices. An adeno‐associated virus (AAV) serotype‐9 vector expressing anti‐ grik2 miRNA was engineered to specifically downregulate GluK2 expression. Direct delivery of AAV9‐anti grik2 miRNA into the hippocampus of TLE mice led to a marked reduction in seizure activity. Transduction of TLE patient hippocampal slices reduced levels of GluK2 protein and, most importantly, significantly reduced IEDs.

Interpretation

Our gene silencing strategy to knock down aberrant GluK2 expression demonstrates inhibition of chronic seizure in a mouse TLE model and IEDs in cultured slices derived from TLE patients. These results provide proof‐of‐concept for a gene therapy approach targeting GluK2 KARs for drug‐resistant TLE patients. ANN NEUROL 2023;94:745–761

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epilepsy, Temporal LobeDrug Resistant EpilepsyMicroRNAsHumansMiceAnimalsTemporal LobeHippocampusSeizures

Substanzen

MicroRNAs

Autor:innen und Institutionen

  • Aix-Marseille Univ. INSERM, Marseille, France.
  • Univ. Bordeaux, CNRS, Interdisciplinary Institute for Neuroscience IINS, UMR 5297, Bordeaux, France.
  • APHM, INSERM, Aix Marseille Univ, INS, Timone Hospital, Pediatric Neurosurgery, Marseille, France.
  • APHM, INSERM, Aix Marseille Univ, INS, Timone Hospital, Epileptology Department, Marseille, France.
  • REGENXBIO, Rockville, MD, USA.
  • Corlieve Therapeutics SAS, uniQure NV, Paris, France.

ORCID-Profile: Fabrice Bartolomei, Haley Janowitz, Stanislas Lagarde, Christophe Mulle

Förderung

  • Agence Nationale de la Recherche
  • Centre National de la Recherche Scientifique
  • Inserm Transfert
  • Institut National de la Santé et de la Recherche Médicale
  • REGENXBIO

Zitieren

APA

Boileau, C., Deforges, S., Peret, A., Scavarda, D., Bartolomei, F., Giles, A., Partouche, N., Gautron, J., Viotti, J., Janowitz, H., Penchet, G., Marchal, C., Lagarde, S., Trebuchon, A., Villeneuve, N., Rumi, J., Marissal, T., Khazipov, R., Khalilov, I., …, & Crépel, V. (2023). GluK2 Is a Target for Gene Therapy in Drug‐Resistant Temporal Lobe Epilepsy. Annals of Neurology, 94(4), 745-761. https://doi.org/10.1002/ana.26723

Vancouver

Boileau C, Deforges S, Peret A, Scavarda D, Bartolomei F, Giles A, et al. GluK2 Is a Target for Gene Therapy in Drug‐Resistant Temporal Lobe Epilepsy. Annals of Neurology. 2023;94(4):745-761. doi:10.1002/ana.26723

BibTeX
@article{Boileau2023,
  author = {Boileau, Céline and Deforges, Severine and Peret, Angélique and Scavarda, Didier and Bartolomei, Fabrice and Giles, April and Partouche, Nicolas and Gautron, Justine and Viotti, Julio and Janowitz, Haley and Penchet, Guillaume and Marchal, Cécile and Lagarde, Stanislas and Trebuchon, Agnès and Villeneuve, Nathalie and Rumi, Julie and Marissal, Thomas and Khazipov, Roustem and Khalilov, Ilgam and Martineau, Fanny and Maréchal, Marine and Lepine, Anne and Milh, Mathieu and Figarella-Branger, Dominique and Dougy, Etienne and Tong, Soutsakhone and Appay, Romain and Baudouin, Stéphane and Mercer, Andrew and Smith, Jared B and Danos, Olivier and Porter, Richard and Mulle, Christophe and Crépel, Valérie},
  title = {GluK2 Is a Target for Gene Therapy in Drug‐Resistant Temporal Lobe Epilepsy},
  journal = {Annals of Neurology},
  year = {2023},
  volume = {94},
  number = {4},
  pages = {745--761},
  doi = {10.1002/ana.26723}
}
Kostenlos starten →